MNPR FY2026 EPS Estimate Lifted by Brookline Capital Markets

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at Brookline Capital Markets lifted their FY2026 EPS estimates for Monopar Therapeutics in a note issued to investors on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($2.70) for the year, up from their previous estimate of ($2.88). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.96) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($0.81) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02.

MNPR has been the subject of a number of other research reports. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. Morgan Stanley reaffirmed an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday. Barclays reiterated an “overweight” rating and issued a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a research report on Thursday, August 13th. BTIG Research boosted their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, HC Wainwright increased their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $118.67.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $123.84 on Thursday. The firm has a fifty day moving average price of $99.68 and a two-hundred day moving average price of $72.61. Monopar Therapeutics has a fifty-two week low of $29.18 and a fifty-two week high of $124.82. The firm has a market cap of $830.97 million, a price-to-earnings ratio of -57.07 and a beta of 1.47.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics in the third quarter valued at about $28,000. BNP Paribas Financial Markets grew its holdings in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics in the 4th quarter valued at $65,000. Caitong International Asset Management Co. Ltd bought a new position in Monopar Therapeutics during the 4th quarter worth $86,000. Finally, JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.